Hostname: page-component-745bb68f8f-5r2nc Total loading time: 0 Render date: 2025-01-13T21:48:20.198Z Has data issue: false hasContentIssue false
  • English
  • Français

Current (but not ex) cigarette smoking is associated with worse cognitive performances in schizophrenia: results from the FACE-SZ cohort

Published online by Cambridge University Press:  08 September 2022

Jasmina Mallet Open the ORCID record for Jasmina Mallet [Opens in a new window] ,
Ophélia Godin ,
Yecodji Dansou ,
Nicolas Mazer ,
Claire Scognamiglio ,
Fabrice Berna ,
Laurent Boyer ,
Delphine Capdevielle ,
Isabelle Chéreau  and
Thierry D'Amato
...Show all authors
Jasmina Mallet*
Affiliation:
University of Paris, INSERM UMR1266, Institute of Psychiatry and Neuroscience of Paris, Paris, France AP-HP, Department of Psychiatry, Louis Mourier Hospital, Colombes, France Fondation Fondamental, Créteil, France
Ophélia Godin
Affiliation:
Fondation Fondamental, Créteil, France Université Paris-Est, UMR_S955, UPEC, Créteil, France Inserm, U955, Equipe 15 Psychiatrie génétique, Créteil, France AP-HP, Hôpital H. Mondor-A. Chenevier, Pôle de psychiatrie, Créteil, France Fondation FondaMental, fondation de cooperation scientifique, Créteil, France
Yecodji Dansou
Affiliation:
Fondation Fondamental, Créteil, France
Nicolas Mazer
Affiliation:
University of Paris, INSERM UMR1266, Institute of Psychiatry and Neuroscience of Paris, Paris, France AP-HP, Department of Psychiatry, Louis Mourier Hospital, Colombes, France Fondation Fondamental, Créteil, France
Claire Scognamiglio
Affiliation:
University of Paris, INSERM UMR1266, Institute of Psychiatry and Neuroscience of Paris, Paris, France AP-HP, Department of Psychiatry, Louis Mourier Hospital, Colombes, France Fondation Fondamental, Créteil, France
Fabrice Berna
Affiliation:
University of Paris, INSERM UMR1266, Institute of Psychiatry and Neuroscience of Paris, Paris, France Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, INSERM U1114, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg, France
Laurent Boyer
Affiliation:
AP-HM, Aix-Marseille Univ, School of medicine – La Timone Medical Campus, EA 3279: CEReSS – Health Service Research and Quality of Life Center, 27 Boulevard Jean Moulin, 13005 Marseille, France
Delphine Capdevielle
Affiliation:
University of Paris, INSERM UMR1266, Institute of Psychiatry and Neuroscience of Paris, Paris, France Service Universitaire de Psychiatrie Adulte, Hôpital la Colombière, CHRU Montpellier, Université Montpellier 1, Inserm 1061, Montpellier, France
Isabelle Chéreau
Affiliation:
University of Paris, INSERM UMR1266, Institute of Psychiatry and Neuroscience of Paris, Paris, France CHU Clermont-Ferrand, Department of Psychiatry, University of Clermont Auvergne, EA 7280, Clermont-Ferrand, France
Thierry D'Amato
Affiliation:
University of Paris, INSERM UMR1266, Institute of Psychiatry and Neuroscience of Paris, Paris, France INSERM U1028, CNRS UMR5292, Centre de Recherche en Neurosciences de Lyon, Université Claude Bernard Lyon 1, Equipe PSYR2, Centre Hospitalier Le Vinatier, Pole Est, 95 bd Pinel, BP 30039, 69678 Bron Cedex, France
Julien Dubreucq
Affiliation:
University of Paris, INSERM UMR1266, Institute of Psychiatry and Neuroscience of Paris, Paris, France Centre Référent de Réhabilitation Psychosociale et de Remédiation Cognitive (C3R), CH Alpes Isère, France
Guillaume Fond
Affiliation:
University of Paris, INSERM UMR1266, Institute of Psychiatry and Neuroscience of Paris, Paris, France AP-HM, Aix-Marseille Univ, School of medicine – La Timone Medical Campus, EA 3279: CEReSS – Health Service Research and Quality of Life Center, 27 Boulevard Jean Moulin, 13005 Marseille, France
Sylvain Leigner
Affiliation:
University of Paris, INSERM UMR1266, Institute of Psychiatry and Neuroscience of Paris, Paris, France Centre Référent de Réhabilitation Psychosociale et de Remédiation Cognitive (C3R), CH Alpes Isère, France
Pierre-Michel Llorca
Affiliation:
University of Paris, INSERM UMR1266, Institute of Psychiatry and Neuroscience of Paris, Paris, France CHU Clermont-Ferrand, Department of Psychiatry, University of Clermont Auvergne, EA 7280, Clermont-Ferrand, France
David Misdrahi
Affiliation:
University of Paris, INSERM UMR1266, Institute of Psychiatry and Neuroscience of Paris, Paris, France Department of Adult Psychiatry, Charles Perrens Hospital, Bordeaux, France University of Bordeaux, Laboratory of Nutrition and Integrative Neurobiology (UMR INRA 1286), Bordeaux, France
Christine Passerieux
Affiliation:
University of Paris, INSERM UMR1266, Institute of Psychiatry and Neuroscience of Paris, Paris, France Department of Adult Psychiatry and Addictology, Versailles Hospital, Centre Hospitalier de Versailles, 177 rue de Versailles, 78157 Le Chesnay, France DisAP-DevPsy-CESP, INSERM UMR1018, University of Paris-Saclay, University of Versailles Saint-Quentin-En-Yvelines 94807, Villejuif, France
Romain Rey
Affiliation:
University of Paris, INSERM UMR1266, Institute of Psychiatry and Neuroscience of Paris, Paris, France INSERM U1028, CNRS UMR5292, Centre de Recherche en Neurosciences de Lyon, Université Claude Bernard Lyon 1, Equipe PSYR2, Centre Hospitalier Le Vinatier, Pole Est, 95 bd Pinel, BP 30039, 69678 Bron Cedex, France
Baptiste Pignon
Affiliation:
Université Paris-Est, UMR_S955, UPEC, Créteil, France Inserm, U955, Equipe 15 Psychiatrie génétique, Créteil, France AP-HP, Hôpital H. Mondor-A. Chenevier, Pôle de psychiatrie, Créteil, France Fondation FondaMental, fondation de cooperation scientifique, Créteil, France
Mathieu Urbach
Affiliation:
University of Paris, INSERM UMR1266, Institute of Psychiatry and Neuroscience of Paris, Paris, France Department of Adult Psychiatry and Addictology, Versailles Hospital, Centre Hospitalier de Versailles, 177 rue de Versailles, 78157 Le Chesnay, France DisAP-DevPsy-CESP, INSERM UMR1018, University of Paris-Saclay, University of Versailles Saint-Quentin-En-Yvelines 94807, Villejuif, France
Benoit Schorr
Affiliation:
University of Paris, INSERM UMR1266, Institute of Psychiatry and Neuroscience of Paris, Paris, France Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, INSERM U1114, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg, France
Franck Schürhoff
Affiliation:
Université Paris-Est, UMR_S955, UPEC, Créteil, France Inserm, U955, Equipe 15 Psychiatrie génétique, Créteil, France AP-HP, Hôpital H. Mondor-A. Chenevier, Pôle de psychiatrie, Créteil, France Fondation FondaMental, fondation de cooperation scientifique, Créteil, France
Le Strat Yann
Affiliation:
University of Paris, INSERM UMR1266, Institute of Psychiatry and Neuroscience of Paris, Paris, France AP-HP, Department of Psychiatry, Louis Mourier Hospital, Colombes, France Fondation Fondamental, Créteil, France
Caroline Dubertret
Affiliation:
University of Paris, INSERM UMR1266, Institute of Psychiatry and Neuroscience of Paris, Paris, France AP-HP, Department of Psychiatry, Louis Mourier Hospital, Colombes, France Fondation Fondamental, Créteil, France
FACE-SZ (FondaMental Academic Center of Expertise for Schizophrenia) Group
Affiliation:
University of Paris, INSERM UMR1266, Institute of Psychiatry and Neuroscience of Paris, Paris, France AP-HP, Department of Psychiatry, Louis Mourier Hospital, Colombes, France Fondation Fondamental, Créteil, France
*
Author for correspondence: Jasmina Mallet, E-mail: jasmina.mallet@gmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Tobacco use is common in subjects with schizophrenia (SZ) and has sometimes been associated with better functioning in short-term studies. Only few studies embrace an extensive examination of tobacco influence on clinical, cognitive and therapeutic characteristics in stabilized SZ outpatients. The objective of the present study was to assess the association between cognitive performances and smoking status in SZ subjects.

Methods

In total, 1233 SZ participants (73.9% men, mean age 31.5) were included and tested with a comprehensive battery. Tobacco status was self-declared (never-, ex-, or current smokers). Multivariable analyses including principal component analyses (PCA) were used.

Results

In total, 53.7% were smokers with 33.7% of them nicotine-dependent. Multiple factor analysis revealed that current tobacco smoking was associated with impaired general intellectual ability and abstract reasoning (aOR 0.60, 95% IC 0.41–0.88, p = 0.01) and with a lifetime alcohol use disorder (p = 0.026) and a lifetime cannabis use disorder (p < 0.001). Ex- and never-smokers differed for age, mean outcome, cannabis history and medication [ex-smokers being older (p = 0.047), likely to have higher income (p = 0.026), a lifetime cannabis use disorder (p < 0.001) and higher CPZeq doses (p = 0.005)]. Premorbid IQ in the three groups significantly differed with, from higher to lower: ex-smokers, never-smoker, current smokers (all p < 0.001).

Conclusions

This study is the largest to date providing strong evidence that chronic smoking is associated with cognitive impairment in SZ, arguing against the self-medication hypothesis as a contributor to the high prevalence of smoking in SZ. Ex-smokers may also represent a specific subgroup. Longitudinal studies are warranted to determine the developmental impact of tobacco on neurocognition.

Keywords

Attentioncognitionnicotinepsychosissmokingtobacco
Type
Original Article
Information
Psychological Medicine , Volume 53 , Issue 11 , August 2023 , pp. 5279 - 5290
Check for updates
Copyright
Copyright © The Author(s), 2022. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

*

List of FondaMental Advanced Center of Expertise (FACE-SZ) collaborators:

FACE-SZ Clinical Coordinating Center (Fondation FondaMental); F. Berna, E. Haffen, M. Leboyer, PM Llorca and F. Schürhoff;

FACE-SZ Data Coordinating Center (Fondation FondaMental); V. Barteau, S. Bensalem, O. Godin, H. Laouamri and K. Souryis;

FACE-SZ Clinical Sites and Principal Collaborators in France;

AP-HP, INSERM U955, Translational Psychiatry Team, DHU Pe-PSY, Centre Expert Schizophrénie, Pôle de Psychiatrie et d'Addictologie des Hôpitaux Universitaires Henri Mondor, Paris Est University, 40 rue de Mesly, 94000 Créteil, France; E. Bourguignon, M. Leboyer, B. Pignon, J. Petrucci, F. Schürhoff, A. Szöke, G. Wahiche; Department of Adult Psychiatry, Charles Perrens Hospital, F-33076 Bordeaux, France; Laboratory of Nutrition and Integrative Neurobiology (UMR INRA 1286), University of Bordeaux, France: B. Aouizerate; Department of Adult Psychiatry, Charles Perrens Hospital, F-33076 Bordeaux; University of Bordeaux, CNRS UMR 5287-INCIA, Bordeaux, France: A. Deloge, D. Misdrahi and E. Vilà; CHU Clermont-Ferrand, Department of Psychiatry (service de psychatrie B), University of Clermont Auvergne, Clermont-Ferrand, France: O. Blanc, I. Chéreau, H. Denizot, RM. Honciuc, D. Lacelle, PM. Llorca and S. Pires; AP-HP, Department of Psychiatry, Louis Mourier Hospital, Colombes, Inserm UMR1266, Institute of Psychiatry and Neurosciences of Paris, University Paris Descartes, Université Paris Diderot, Sorbonne Paris Cité, Faculté de médecine, France: C. Dubertret, J. Mallet and C. Portalier; Psychosocial Rehabilitation Reference Center, Alpes Isère Hospital, Grenoble, France: J. Dubreucq, C. Fluttaz, F. Gabayet and C. Roman; University Claude Bernard Lyon 1, Le Vinatier Hospital Pole Est BP 300 39–95 bd Pinel – 69678 Bron Cedex, France: G. Chesnoy-Servanin, T. D'Amato, JM. Dorey, R. Rey and A. Vehier; Department of Psychiatry (AP-HM), Sainte-Marguerite University Hospital, Marseille, France: C. Lançon, C. Faget, E. Metairie, P. Peri and F. Vaillant; AP-HM, la Conception Hospital, Aix-Marseille Univ, School of medicine – La Timone Medical Campus, EA 3279: CEReSS – Health Service Research: L. Boyer and G. Fond; Strasbourg University Hospital, University of Strasbourg, INSERM U1114, Federation of Translational Psychiatry, Strasbourg, France: F. Berna, P. Vidailhet and A. Zinetti-Bertschy; University Department of Adult Psychiatry, La Colombiere Hospital, CHU Montpellier, University of Montpellier 1, Inserm 1061, Montpellier, France: D. Capdevielle and H. Yazbek; Versailles Hospital, Department of Adult Psychiatry and Addictology, Centre Hospitalier de Versailles, 177 rue de Versailles, 78157 Le Chesnay, France; DisAP-DevPsy-CESP, INSERM UMR1018, University of Paris-Saclay, University of Versailles Saint-Quentin-En-Yvelines 94807, Villejuif, France: S. Esselin, M. Jarroir, C. Passerieux and M. Urbach

References

Ahlers, E., Hahn, E., Ta, T. M. T., Goudarzi, E., Dettling, M., & Neuhaus, A. H. (2014). Smoking improves divided attention in schizophrenia. Psychopharmacology, 231(19), 3871–3877. https://doi.org/10.1007/s00213-014-3525-2.CrossRefGoogle ScholarPubMed
Bender, R., & Lange, S. (2001). Adjusting for multiple testing – when and how? Journal of Clinical Epidemiology, 54(4), 343–349.CrossRefGoogle ScholarPubMed
Bernard, D., Lançon, C., Auquier, P., Reine, G., & Addington, D. (1998). Calgary Depression Scale for Schizophrenia: A study of the validity of a French-language version in a population of schizophrenic patients. Acta Psychiatrica Scandinavica, 97(1), 36–41.CrossRefGoogle Scholar
Boggs, D. L., Surti, T. S., Esterlis, I., Pittman, B., Cosgrove, K., Sewell, R. A., … D'Souza, D. C. (2018). Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the ‘self-medication’ hypothesis in schizophrenia. Schizophrenia Research, 194, 62–69. https://doi.org/10.1016/j.schres.2017.03.047.CrossRefGoogle ScholarPubMed
Coustals, N., Martelli, C., Brunet-Lecomte, M., Petillion, A., Romeo, B., & Benyamina, A. (2020). Chronic smoking and cognition in patients with schizophrenia: A meta-analysis. Schizophrenia Research, 222, 113–121. https://doi.org/10.1016/j.schres.2020.03.071.CrossRefGoogle ScholarPubMed
de Leon, J., & Diaz, F. J. (2005). A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophrenia Research, 76(2–3), 135–157. https://doi.org/10.1016/j.schres.2005.02.010.CrossRefGoogle ScholarPubMed
Delis, D. C., Kramer, J. H., Kaplan, E., & Ober, B. A. (2000). California verbal learning test-adult version (2nd ed.), San Antonio: Psychological Corporation.Google Scholar
Dondé, C., Brunelin, J., Mondino, M., Cellard, C., Rolland, B., & Haesebaert, F. (2020). The effects of acute nicotine administration on cognitive and early sensory processes in schizophrenia: A systematic review. Neuroscience and Biobehavioral Reviews, 118, 121–133. https://doi.org/10.1016/j.neubiorev.2020.07.035.CrossRefGoogle ScholarPubMed
Endicott, J., Spitzer, R. L., Fleiss, J. L., & Cohen, J. (1976). The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry, 33(6), 766–771.CrossRefGoogle Scholar
Etter, M., Mohr, S., Garin, C., & Etter, J.-F. (2004). Stages of change in smokers with schizophrenia or schizoaffective disorder and in the general population. Schizophrenia Bulletin, 30(2), 459–468. https://doi.org/10.1093/oxfordjournals.schbul.a007092.CrossRefGoogle ScholarPubMed
First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. W. (2002). Structured Clinical Interview for DSM -IV-TR Axis I disorders, research version. New York: Biometrics research, New York State Psychiatric Institute.Google Scholar
Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., … Byerley, W. (1997). Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proceedings of the National Academy of Sciences of the USA, 94(2), 587–592. https://doi.org/10.1073/pnas.94.2.587.CrossRefGoogle ScholarPubMed
Gage, S. H., & Munafò, M. R. (2015). Smoking as a causal risk factor for schizophrenia. The Lancet. Psychiatry, 2(9), 778–779. https://doi.org/10.1016/S2215-0366(15)00333-8.CrossRefGoogle ScholarPubMed
Guignard, R., Beck, F., Wilquin, J. L., Andler, V., Nguyen-Thanh, V., Richard, J. B., & Arwidson, P. (2015). La consommation de tabac en France et son évolution: Résultats du Baromètre santé 2014. Bulletin Epidémiologique Hebdomadaire (17–18), 281–288.Google Scholar
Gurillo, P., Jauhar, S., Murray, R. M., & MacCabe, J. H. (2015). Does tobacco use cause psychosis? Systematic review and meta-analysis. The Lancet Psychiatry, 2(8), 718–725. https://doi.org/10.1016/S2215-0366(15)00152-2.CrossRefGoogle ScholarPubMed
Hahn, B., Harvey, A. N., Concheiro-Guisan, M., Huestis, M. A., Holcomb, H. H., & Gold, J. M. (2013). A test of the cognitive self-medication hypothesis of tobacco smoking in schizophrenia. Biological Psychiatry, 74(6), 436–443. https://doi.org/10.1016/j.biopsych.2013.03.017.CrossRefGoogle ScholarPubMed
Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., & Fagerström, K. O. (1991). The Fagerström test for nicotine dependence: A revision of the Fagerström tolerance questionnaire. British Journal of Addiction, 86(9), 1119–1127. https://doi.org/10.1111/j.1360-0443.1991.tb01879.x.CrossRefGoogle ScholarPubMed
Heishman, S. J., Kleykamp, B. A., & Singleton, E. G. (2010). Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology, 210(4), 453–469. https://doi.org/10.1007/s00213-010-1848-1.CrossRefGoogle ScholarPubMed
Hindocha, C., Brose, L. S., Walsh, H., & Cheeseman, H. (2021). Cannabis use and co-use in tobacco smokers and non-smokers: Prevalence and associations with mental health in a cross-sectional, nationally representative sample of adults in Great Britain, 2020. Addiction (Abingdon, England), 116(8), 2209–2219. https://doi.org/10.1111/add.15381.CrossRefGoogle Scholar
Howes, O. D., Kambeitz, J., Kim, E., Stahl, D., Slifstein, M., Abi-Dargham, A., & Kapur, S. (2012). The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Archives of General Psychiatry, 69(8), 776–786. https://doi.org/10.1001/archgenpsychiatry.2012.169.CrossRefGoogle ScholarPubMed
Kahn, R. S., & Keefe, R. S. E. (2013). Schizophrenia is a cognitive illness: Time for a change in focus. JAMA Psychiatry, 70(10), 1107–1112. https://doi.org/10.1001/jamapsychiatry.2013.155.CrossRefGoogle ScholarPubMed
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2), 261–276.CrossRefGoogle ScholarPubMed
Kendler, K. S., Lönn, S. L., Sundquist, J., & Sundquist, K. (2015). Smoking and schizophrenia in population cohorts of Swedish women and men: A prospective co-relative control study. The American Journal of Psychiatry, 172(11), 1092–1100. https://doi.org/10.1176/appi.ajp.2015.15010126.CrossRefGoogle Scholar
Leonard, S., Adler, L. E., Benhammou, K., Berger, R., Breese, C. R., Drebing, C., … Freedman, R. (2001). Smoking and mental illness. Pharmacology, Biochemistry, and Behavior, 70(4), 561–570.CrossRefGoogle ScholarPubMed
Leucht, S., Samara, M., Heres, S., Patel, M. X., Furukawa, T., Cipriani, A., … Davis, J. M. (2015). Dose equivalents for second-generation antipsychotic drugs: The classical mean dose method. Schizophrenia Bulletin, 41(6), 1397–1402. https://doi.org/10.1093/schbul/sbv037.CrossRefGoogle ScholarPubMed
Liao, W., Fan, Y.-S., Yang, S., Li, J., Duan, X., Cui, Q., & Chen, H. (2019). Preservation effect: Cigarette smoking acts on the dynamic of influences among unifying neuropsychiatric triple networks in schizophrenia. Schizophrenia Bulletin, 45(6), 1242–1250. https://doi.org/10.1093/schbul/sby184.CrossRefGoogle ScholarPubMed
Lucatch, A. M., Lowe, D. J. E., Clark, R. C., Kozak, K., & George, T. P. (2018). Neurobiological determinants of tobacco smoking in schizophrenia. Frontiers in Psychiatry, 9, 672. https://doi.org/10.3389/fpsyt.2018.00672.CrossRefGoogle ScholarPubMed
Ma, Y., Li, J., Xu, Y., Wang, Y., Yao, Y., Liu, Q., … Li, M. D. (2020). Identification of 34 genes conferring genetic and pharmacological risk for the comorbidity of schizophrenia and smoking behaviors. Aging, 12(3), 2169–2225. https://doi.org/10.18632/aging.102735.CrossRefGoogle ScholarPubMed
Mallet, J., Godin, O., Le Strat, Y., Mazer, N., Berna, F., & Boyer, L., … FACE-SZ (FondaMental Academic Center of Expertise for Schizophrenia Group). (2021). Handedness as a neurodevelopmental marker in schizophrenia: Results from the FACE-SZ cohort. The World Journal of Biological Psychiatry: The Official Journal of the World Federation of Societies of Biological Psychiatry, Dec 17; 1–12. https://doi.org/10.1080/15622975.2021.2013094.Google ScholarPubMed
Mallet, J., Le Strat, Y., Dubertret, C., & Gorwood, P. (2020). Polygenic risk scores shed light on the relationship between schizophrenia and cognitive functioning: Review and meta-analysis. Journal of Clinical Medicine, 9(2), 341. https://doi.org/10.3390/jcm9020341.CrossRefGoogle ScholarPubMed
Mallet, J., Le Strat, Y., Schürhoff, F., Mazer, N., Portalier, C., Andrianarisoa, M., … FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group. (2017a). Cigarette smoking and schizophrenia: A specific clinical and therapeutic profile? Results from the FACE-schizophrenia cohort. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 79(Pt B), 332–339. https://doi.org/10.1016/j.pnpbp.2017.06.026.CrossRefGoogle ScholarPubMed
Mallet, J., Le Strat, Y., Schürhoff, F., Mazer, N., Portalier, C., Andrianarisoa, M., … FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group. (2018). Tobacco smoking is associated with antipsychotic medication, physical aggressiveness, and alcohol use disorder in schizophrenia: Results from the FACE-SZ national cohort. European Archives of Psychiatry and Clinical Neuroscience, 269(4), 449–457. https://doi.org/10.1007/s00406-018-0873-7.CrossRefGoogle ScholarPubMed
Mallet, J., Ramoz, N., Le Strat, Y., Gorwood, P., & Dubertret, C. (2017b). Heavy cannabis use prior psychosis in schizophrenia: Clinical, cognitive and neurological evidences for a new endophenotype? European Archives of Psychiatry and Clinical Neuroscience, 267(7), 629–638. https://doi.org/10.1007/s00406-017-0767-0.CrossRefGoogle ScholarPubMed
Misdrahi, D., Verdoux, H., Llorca, P.-M., & Baylé, F.-J. (2004). [Therapeutic adherence and schizophrenia: The interest of the validation of the French translation of Medication Adherence Rating Scale (MARS)]. L'Encephale, 30(4), 409–410.Google ScholarPubMed
Novak, G., Seeman, P., & Le Foll, B. (2010). Exposure to nicotine produces an increase in dopamine D2(High) receptors: A possible mechanism for dopamine hypersensitivity. The International Journal of Neuroscience, 120(11), 691–697. https://doi.org/10.3109/00207454.2010.513462.CrossRefGoogle ScholarPubMed
Nuechterlein, K. H., Green, M. F., Kern, R. S., Baade, L. E., Barch, D. M., Cohen, J. D., … Marder, S. R. (2008). The MATRICS Consensus Cognitive Battery, part 1: Test selection, reliability, and validity. The American Journal of Psychiatry, 165(2), 203–213. https://doi.org/10.1176/appi.ajp.2007.07010042.CrossRefGoogle ScholarPubMed
Pasquereau, A. (s. d.). Consommation de tabac parmi les adultes en 2020: Résultats du baromètre de Santé Publique France/tobacco use among adults in 2020: Results from the Santé Publique France health barometer. 8.Google Scholar
Register-Brown, K., & Hong, L. E. (2014). Reliability and validity of methods for measuring the duration of untreated psychosis: A quantitative review and meta-analysis. Schizophrenia Research, 160(1–3), 20–26. https://doi.org/10.1016/j.schres.2014.10.025.CrossRefGoogle ScholarPubMed
Reitan, R. M. (1958). Validity of the trail making test as an indicator of organic brain damage. Perceptual and Motor Skills, 8(3), 271–276. https://doi.org/10.2466/pms.1958.8.3.271.CrossRefGoogle Scholar
Sacco, K. A., Termine, A., Seyal, A., Dudas, M. M., Vessicchio, J. C., Krishnan-Sarin, S., … George, T. P. (2005). Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: Involvement of nicotinic receptor mechanisms. Archives of General Psychiatry, 62(6), 649–659. https://doi.org/10.1001/archpsyc.62.6.649.CrossRefGoogle ScholarPubMed
Schneider, C. E., White, T., Hass, J., Geisler, D., Wallace, S. R., Roessner, V., … Ehrlich, S. (2014). Smoking status as a potential confounder in the study of brain structure in schizophrenia. Journal of Psychiatric Research, 50, 84–91. https://doi.org/10.1016/j.jpsychires.2013.12.004.CrossRefGoogle Scholar
Schürhoff, F., Fond, G., Berna, F., Bulzacka, E., Vilain, J., & Capdevielle, D., … FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) collaborators. (2015). A national network of schizophrenia expert centres: An innovative tool to bridge the research-practice gap. European Psychiatry: The Journal of the Association of European Psychiatrists, 30(6), 728–735. https://doi.org/10.1016/j.eurpsy.2015.05.004.CrossRefGoogle ScholarPubMed
Tabachnick, B., & Fidel, L. (2001). Using multivariate statistics. Boston, MA: Allyn and Bacon Pearson Education Company. Consulté 9 décembre 2021, à l'adresse. https://www.google.com/search?client=firefox-b-e&q=TABACHNICK+BG%2C+Fidel+LZ.+Using+multivariate+statistics.+Boston%2C+MA%3A+Allyn+and+Bacon+Pearson+Education+Company%2C+2001.Google Scholar
Tidey, J. W., Colby, S. M., & Xavier, E. M. H. (2014). Effects of smoking abstinence on cigarette craving, nicotine withdrawal, and nicotine reinforcement in smokers with and without schizophrenia. Nicotine & Tobacco Research, 16(3), 326–334. https://doi.org/10.1093/ntr/ntt152.CrossRefGoogle ScholarPubMed
Tregellas, J. R., Shatti, S., Tanabe, J. L., Martin, L. F., Gibson, L., Wylie, K., & Rojas, D. C. (2007). Gray matter volume differences and the effects of smoking on gray matter in schizophrenia. Schizophrenia Research, 97(1–3), 242–249. https://doi.org/10.1016/j.schres.2007.08.019.CrossRefGoogle ScholarPubMed
Vermeulen, J. M., Schirmbeck, F., Blankers, M., van Tricht, M., Bruggeman, R., van den Brink, W., … Genetic Risk and Outcome of Psychosis (GROUP) investigators. (2018). Association between smoking behavior and cognitive functioning in patients with psychosis, siblings, and healthy control subjects: Results from a prospective 6-year follow-up study. The American Journal of Psychiatry, 175(11), 1121–1128. https://doi.org/10.1176/appi.ajp.2018.18010069.CrossRefGoogle ScholarPubMed
Wing, V. C., Bacher, I., Sacco, K. A., & George, T. P. (2011). Neuropsychological performance in patients with schizophrenia and controls as a function of cigarette smoking status. Psychiatry Research, 188(3), 320–326. https://doi.org/10.1016/j.psychres.2011.05.037.CrossRefGoogle ScholarPubMed
Yee, A., Bt Nek Mohamed, N. N., Binti Hashim, A. H., Loh, H. S., Harbajan Singh, M. K., Ng, C. G., & Jambunathan, S. T. (2015). The effect of nicotine dependence on psychopathology in patients with schizophrenia. BioMed Research International, 2015, 730291. https://doi.org/10.1155/2015/730291.CrossRefGoogle ScholarPubMed
Yokoyama, N., Sasaki, H., Mori, Y., Ono, M., Tsurumi, K., Kawada, R., … Takahashi, H. (2018). Additive effect of cigarette smoking on gray matter abnormalities in schizophrenia. Schizophrenia Bulletin, 44(3), 535–541. https://doi.org/10.1093/schbul/sbx092.Google ScholarPubMed
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978). A rating scale for mania: Reliability, validity and sensitivity. The British Journal of Psychiatry, 133(5), 429–435. https://doi.org/10.1192/bjp.133.5.429.CrossRefGoogle ScholarPubMed
Supplementary material: File

Mallet et al. supplementary material

Tables S1-S3

Download Mallet et al. supplementary material(File)
File 45.5 KB